[go: up one dir, main page]

MX2013003890A - Composiciones y metodos para tratar edema ocular, neovascularizacion y enfermedades relacionadas. - Google Patents

Composiciones y metodos para tratar edema ocular, neovascularizacion y enfermedades relacionadas.

Info

Publication number
MX2013003890A
MX2013003890A MX2013003890A MX2013003890A MX2013003890A MX 2013003890 A MX2013003890 A MX 2013003890A MX 2013003890 A MX2013003890 A MX 2013003890A MX 2013003890 A MX2013003890 A MX 2013003890A MX 2013003890 A MX2013003890 A MX 2013003890A
Authority
MX
Mexico
Prior art keywords
neovascularization
edema
ocular
methods
compositions
Prior art date
Application number
MX2013003890A
Other languages
English (en)
Inventor
Robert Shalwitz
Kevin G Peters
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of MX2013003890A publication Critical patent/MX2013003890A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se dan a conocer métodos para el tratamiento de enfermedades o afecciones de los ojos, especialmente retinopatías, edema ocular y neovascularización ocular; los ejemplos no limitativos de estas enfermedades o afecciones incluyen edema macular diabético, degeneración macular relacionada con la edad (forma húmeda), neovascularización coroidea, retinopatía diabética, oclusión (central o ramificada) de venas retinianas, trauma ocular, edema inducido por cirugía, neovascularización inducida por cirugía, edema macular cistoide, isquemia ocular, uveítis y otros similares.
MX2013003890A 2010-10-07 2011-10-05 Composiciones y metodos para tratar edema ocular, neovascularizacion y enfermedades relacionadas. MX2013003890A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39089910P 2010-10-07 2010-10-07
PCT/US2011/054873 WO2012047966A2 (en) 2010-10-07 2011-10-05 Compositions and methods for treating ocular edema, neovascularization and related diseases

Publications (1)

Publication Number Publication Date
MX2013003890A true MX2013003890A (es) 2014-03-12

Family

ID=45928396

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013003890A MX2013003890A (es) 2010-10-07 2011-10-05 Composiciones y metodos para tratar edema ocular, neovascularizacion y enfermedades relacionadas.
MX2017006194A MX361520B (es) 2010-10-07 2011-10-05 Composiciones y métodos para tratar edema ocular, neovascularización y enfermedades relacionadas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017006194A MX361520B (es) 2010-10-07 2011-10-05 Composiciones y métodos para tratar edema ocular, neovascularización y enfermedades relacionadas.

Country Status (16)

Country Link
US (3) US20120129847A1 (es)
EP (1) EP2624916B1 (es)
JP (4) JP2013539756A (es)
KR (2) KR101823924B1 (es)
CN (2) CN103347565A (es)
AU (2) AU2011312203C1 (es)
BR (1) BR112013008452A2 (es)
CA (2) CA2890554A1 (es)
IL (1) IL229786A (es)
MX (2) MX2013003890A (es)
MY (1) MY176514A (es)
NZ (2) NZ610230A (es)
PH (1) PH12013500577B1 (es)
RU (1) RU2600794C2 (es)
SG (1) SG189177A1 (es)
WO (1) WO2012047966A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5166398B2 (ja) 2006-04-07 2013-03-21 エアーピオ セラピューティクス インコーポレイテッド ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
JP5536113B2 (ja) 2009-07-06 2014-07-02 アケビア セラピューティクス インコーポレイテッド がん細胞の転移を予防するための化合物、組成物および方法
BR112012010766A2 (pt) 2009-11-06 2015-10-06 Aerpio Therapeutics Inc composições e métodos de tratamento da colite e de outras doenças instestinais
EP2766044B1 (en) 2011-10-13 2019-12-11 Aerpio Therapeutics, Inc. Treatment of ocular disease
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2014113407A2 (en) 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
EP4101297A1 (en) * 2013-03-15 2022-12-14 Aerpio Pharmaceuticals, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3381940B1 (en) 2013-07-29 2022-09-07 Samsung Electronics Co., Ltd. Anti-ang2 antibody
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
JP6699551B2 (ja) 2014-07-15 2020-05-27 アステラス製薬株式会社 新規抗ヒトＴｉｅ２抗体
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
RU2587779C1 (ru) * 2015-04-27 2016-06-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Композиция для ингибирования и комплексного лечения интраоперационного макулярного отека
MY194736A (en) 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2194528C2 (ru) * 1996-05-31 2002-12-20 Дзе Скриппс Рисерч Инститьют Способы и композиции, используемые для ингибирования ангиогенеза
JP5032299B2 (ja) * 2004-03-24 2012-09-26 シャイア・オーファン・セラピーズ・ゲーエムベーハー 血管形成を阻害する新規化合物及びその使用
PL1968594T3 (pl) * 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
JP2009525282A (ja) * 2006-01-30 2009-07-09 （オーエスアイ）アイテツク・インコーポレーテツド 血管新生疾患の治療のための組み合わせ療法
JP5166398B2 (ja) * 2006-04-07 2013-03-21 エアーピオ セラピューティクス インコーポレイテッド ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN101506180B (zh) * 2006-06-27 2013-10-30 艾尔普罗医疗有限公司 人蛋白酪氨酸磷酸酶抑制剂及使用方法
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN102365023A (zh) * 2009-01-12 2012-02-29 阿克比治疗有限公司 治疗血管渗漏综合征的方法
JP5536113B2 (ja) * 2009-07-06 2014-07-02 アケビア セラピューティクス インコーポレイテッド がん細胞の転移を予防するための化合物、組成物および方法

Also Published As

Publication number Publication date
BR112013008452A2 (pt) 2016-06-28
US20120129847A1 (en) 2012-05-24
CN106562962A (zh) 2017-04-19
MY176514A (en) 2020-08-12
JP6243882B2 (ja) 2017-12-06
CA2890554A1 (en) 2012-04-12
KR20140027055A (ko) 2014-03-06
JP2018021083A (ja) 2018-02-08
WO2012047966A3 (en) 2012-06-28
AU2016204410B2 (en) 2018-10-04
WO2012047966A8 (en) 2013-05-16
RU2600794C2 (ru) 2016-10-27
AU2016204410A1 (en) 2016-07-14
RU2013120064A (ru) 2014-11-20
NZ610230A (en) 2015-07-31
AU2011312203B2 (en) 2016-07-28
CN103347565A (zh) 2013-10-09
EP2624916B1 (en) 2018-01-17
AU2011312203A1 (en) 2013-05-02
US20140288134A1 (en) 2014-09-25
JP2013539756A (ja) 2013-10-28
MX361520B (es) 2018-12-06
PH12013500577A1 (en) 2013-05-20
AU2011312203C1 (en) 2016-09-08
SG189177A1 (en) 2013-05-31
KR101823924B1 (ko) 2018-01-31
JP2016027055A (ja) 2016-02-18
US20180037579A1 (en) 2018-02-08
CA2818215C (en) 2015-07-21
NZ705624A (en) 2016-09-30
CA2818215A1 (en) 2012-04-12
IL229786A (en) 2017-02-28
EP2624916A2 (en) 2013-08-14
WO2012047966A4 (en) 2012-08-16
JP2016029062A (ja) 2016-03-03
KR20150023892A (ko) 2015-03-05
PH12013500577B1 (en) 2019-06-28
WO2012047966A2 (en) 2012-04-12
EP2624916A4 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
PH12013500577B1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX2016009331A (es) Composiciones y metodos para tratar enfermedades oculares.
HK1201438A1 (en) Treatment of ocular disease
SG191334A1 (en) Use of a vegf antagonist to treat angiogenic eye disorders
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
HK1198811A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
MX2022001433A (es) Tratamiento personalizado de enfermedades oftalmologicas.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
EA201100462A1 (ru) Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств
WO2011137344A3 (en) Anti-s1p antibody treatment of patients with ocular disease
MX2013001870A (es) Formulaciones oftalmicas de escualamina.
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
WO2009046405A3 (en) Antibodies to htra1 and methods of using the same
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
MX2015006779A (es) Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares.
HK1219654A1 (zh) 用於治疗眼科疾病和病症的方法
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
HK1231694A1 (en) Compositions and methods for treating ocular diseases
WO2012105854A3 (en) Compositions for administration to the eye
HK1189820A (en) Use of a vegf antagonist to treat angiogenic eye disorders